Sutton

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer5 trials
• Endometrial cancer2 trials
• Head and neck cancer2 trials
• Lung cancer2 trials
• Multiple myeloma2 trials
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 36 trials
• Phase 13 trials
• Phase 23 trials

Status

• Active, not recruiting6 trials
• Recruiting5 trials
• Completed1 trial

Lead sponsor

• GlaxoSmithKline10 trials
• Tesaro, Inc.2 trials

Running trials

• Recruiting

  A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

  NCT07286331· Phase 3· GlaxoSmithKline· Source

  Contact: Susan Lalondrelle (principal investigator)

• Recruiting

  A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

  NCT07277270· Phase 1· GlaxoSmithKline· Source

  Contact: Alec Paschalis (principal investigator)

• Recruiting

  A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

  NCT06567782· Phase 2· GlaxoSmithKline· Source

  Contact: Naureen Starling (principal investigator)

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Ben O'Leary (principal investigator)

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

  Contact: Naureen Starling (principal investigator)

• Active, not recruiting

  A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

  NCT05723562· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

  NCT05277051· Phase 1· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

  NCT04484623· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

  NCT02715284· Phase 1· Tesaro, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

  NCT03525678· Phase 2· GlaxoSmithKline· Source